Table II.
Biochemical measurements prior to and following immunosuppressive therapy in patients with IMN.
| Time point | ||||
|---|---|---|---|---|
| Factor measured | Group | Prior to treatment | After treatment | P-value |
| Proteinuria (g/24 h) | All patients | 6.40±3.65 | 1.81±1.70 | <0.001 |
| CTX | 6.02±3.54 | 1.54±1.34 | <0.001 | |
| FK506 | 7.14±3.83 | 2.25±2.17 | <0.001 | |
| Serum albumin (g/l) | All patients | 24.21±6.08 | 35.81±5.74 | <0.001 |
| CTX | 25.31±6.11 | 36.31±5.47 | <0.001 | |
| FK506 | 22.24±5.56 | 34.90±6.24 | <0.001 | |
| eGFR (ml/min/1.73 m2) | All patients | 113.33±36.35 | 113.27±37.59 | 0.84 |
| CTX | 112.72±29.35 | 108.53±27.97 | 0.44 | |
| FK506 | 114.44±47.28 | 121.34±49.75 | 0.23 | |
| PLA2R antibody level (mU/ml) | All patients | 1.25±0.72 | 0.58±0.59 | <0.001 |
| CTX | 1.35±0.66 | 0.82±0.54 | <0.001 | |
| FK506 | 1.05±0.79 | 0.12±0.37 | <0.001 | |
| AR antibody level (mU/ml) | All patients | 16.88±14.10 | 16.45±15.93 | 0.78 |
| CTX | 16.15±12.77 | 14.71±13.88 | 0.42 | |
| FK506 | 18.34±16.80 | 19.94±19.42 | 0.53 | |
| SOD2 antibody level (mU/ml) | All patients | 3.73±6.15 | 4.82±9.63 | 0.92 |
| CTX | 2.87±5.78 | 4.81±11.09 | 0.32 | |
| FK506 | 5.26±6.64 | 4.85±6.44 | 0.23 | |
CTX, cyclophosphamide; FK506, tacrolimus; eGFR, estimated glomerular filtration rate; PLA2R, M-type phospholipase A2 receptor; AR, aldose reductase; SOD, superoxide dismutase.